Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) is a phase 2, interventional study registered as NCT05663775 by AHS Cancer Control Alberta, with a registry enrolment figure of 20 participants, started 2024-08-20 and due to reach its primary completion in 2026-08. Interventions recorded: Mesalamine. Conditions listed: Immune-related Adverse Event; Diarrhea; Advanced Melanoma; Advanced Rectal Carcinoma. Primary outcome: Incidence of Treatment Related Diarrhea; Severity of Treatment Related Diarrhea; Causality of Treatment Related Diarrhea. Colorectal eligibility wording from the registry: "WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal". Sites: Canada. No results are recorded here; the registry entry is the source.